Connect
MJA
MJA

Current prescribing patterns of bupropion in Australia

Christopher M Doran, Anthony P Shakeshaft, Jennifer A Gates, Julia E Fawcett and Richard P Mattick
Med J Aust 2002; 177 (3): 162.
Published online: 5 August 2002

To the Editor: Bupropion hydrochloride was listed on the Pharmaceutical Benefits Scheme (PBS) on 1 February 2001 for use as short-term adjunctive therapy for high nicotine dependence, with the goal of maintaining abstinence. Supply is limited to one application per year, with no repeats, and a maximum quantity of 120 tablets at a dispensed cost of $238.95.

  • Christopher M Doran
  • Anthony P Shakeshaft
  • Jennifer A Gates
  • Julia E Fawcett
  • Richard P Mattick


Correspondence: c.doran@unsw.edu.au

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.